[Decreased bone mineral density in HIV-infected children receiving highly active antiretroviral therapy]

An Pediatr (Barc). 2004 Mar;60(3):249-53. doi: 10.1016/s1695-4033(04)78259-4.
[Article in Spanish]

Abstract

Background: In developed countries, the introduction of highly active antiretroviral therapy (HAART) has greatly improved survival and quality of life in HIV-infected children. Nevertheless, worrisome metabolic and bone alterations are beginning to be observed.

Objective: To evaluate the prevalence of alterations in bone mineral density and possible associated factors in a cohort of HIV-infected children receiving HAART.

Patients and methods: Bone dual energy X-ray absorptiometry (DEXA) was performed in 50 HIV-infected children in a tertiary hospital in Madrid after a median length of HAART of 54 months. Subsequently, the group with bone mineral loss was compared with the group without bone mineral loss.

Results: Forty percent of the children studied had decreased bone mineral density, of which 36 % had osteopenia (18/50) and 4 % had osteoporosis (2/50). No statistically significant differences were found between the two groups in any of the factors analyzed.

Conclusions: The prevalence of decreased bone mineral density in our cohort of HIV-infected children receiving HAART is high. The etiology and factors associated with this alteration are still not well known.

Publication types

  • English Abstract

MeSH terms

  • Antiretroviral Therapy, Highly Active / adverse effects*
  • Bone Density / drug effects*
  • Child
  • Child, Preschool
  • Cross-Sectional Studies
  • Female
  • HIV Infections / drug therapy*
  • Humans
  • Male
  • Surveys and Questionnaires